Conference Report

Coverage of the 2006 International Congress on Drug Therapy in HIV Infection

Source: CCO Independent Conference Coverage of the 2006 International Congress on Drug Therapy in HIV Infection*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Coverage of the 2006 International Congress on Drug Therapy in HIV Infection

Faculty:
Anton L. Pozniak, MD, FRCP Peter Reiss, MD, PhD

CME CREDIT INFORMATION

Release Date: 01/11/07

Expiration Date: 01/10/08

Physicians: maximum of 1.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies investigating the use of antiretroviral agents in the management of treatment-experienced patients
Describe new clinical insights regarding optimal antiretroviral regimens for first-line therapy
Discuss clinical trials evaluating the efficacy and long-term safety of tenofovir DF–containing regimens

Topics covered include:

First-Line Saquinavir/Ritonavir vs Lopinavir/Ritonavir
Once-Daily Fosamprenavir Plus 100 vs 200 mg Ritonavir
First-Line Efavirenz vs Lopinavir/Ritonavir
Tipranavir/Ritonavir as First-Line Therapy
RESIST 96-Week Results
Etravirine in NNRTI-Experienced Patients
Once‑Daily vs Twice‑Daily Enfuvirtide
Increased NNRTI Levels in HIV/HCV-Infected Cirrhotics
Lipid-Lowering Agents vs Switch to NNRTIs
Diabetes Risk Factors in Patients With HIV
Efficacy and Safety of Tenofovir-Based Therapy
Maraviroc Treatment of Dual/Mixed-Tropic Virus

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.